Evidence map›Paper›PMID 31969201›Full record

Trial reportInternational psychogeriatrics2021

[

Beatrix Krause-Sorio, Prabha Siddarth, Kelsey T Laird, Linda Ercoli, Katherine Narr, Jorge R Barrio, Gary Small, Helen Lavretsky

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International psychogeriatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01902004 (Treatment of Geriatric Depression With Mild Cognitive Impairment), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01902004 phase4completednot on this map

Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age

TypeinterventionalSponsorUniversity of California, Los AngelesRan2013 to 2019Enrolled115ConditionsMild Cognitive Impairment (MCI), DepressionArmsEscitalopram, Memantine, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Beatrix Krause-SorioSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0001-5495-6348
Prabha SiddarthSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.
Kelsey T LairdSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-3194-2522
Linda ErcoliSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.
Katherine NarrBrain Research Institute, Los Angeles, CA 90095, USA.
Jorge R BarrioDepartment of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA.
Gary SmallSemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.
Helen LavretskySemel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095, USA.
University of California, Los Angeles · US

Funding

Brain aging and treatment response in geriatric depressionR01MH097892 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2013 to 2017
$3.5M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
NCCIH NIH HHS K24 AT009198NIMH NIH HHS R01 MH097892
6 · The paper itself

Abstract

objectivesGeriatric depression often presents with memory and cognitive complaints that are associated with increased risk for Alzheimer's disease (AD). In a parent clinical trial of escitalopram combined with memantine or placebo for geriatric depression and subjective memory complaints, we found that memantine improved executive function and delayed recall performance at 12 months (NCT01902004). In this report, we used positron emission tomography (PET) to assess the relationship between in-vivo amyloid and tau brain biomarkers and clinical and cognitive treatment response.

designIn a randomized double-blind placebo-controlled trial, we measured 2-(1-{6-[(2-[F18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ([18F]FDDNP) binding at baseline and assessed mood and cognitive performance at baseline, posttreatment (6 months), and naturalistic follow-up (12 months).

participantsTwenty-two older adults with major depressive disorder and subjective memory complaints completed PET scans and were included in this report.

resultsAcross both treatment groups, higher frontal lobe [18F]FDDNP binding at baseline was associated with improvement in executive function at 6 months (corrected p = .045). This effect was no longer significant at 12 months (corrected p = .12). There was no association of regional [18F]FDDNP binding with change in mood symptoms (corrected p = .2).

conclusions[18F]FDDNP binding may predict cognitive response to antidepressant treatment. Larger trials are required to further test the value of [18F]FDDNP binding as a biomarker for cognitive improvement with antidepressant treatment in geriatric depression.

Indexed as

Executive FunctionMemoryPositron-Emission TomographyAgedAlzheimer DiseaseAmyloid beta-PeptidesBrainFemaleHumansMajor Depressive DisorderMalePilot Projectstau ProteinsAmyloid beta-Peptidestau Proteins[18F]FDDNP positron emission tomographyAlzheimer’s diseaseamyloid and tauclinical trialcognitive impairmentescitalopramexecutive functiongeriatric depressionmemantineneuroimaging

Identifiers

PMID31969201
PMCPMC7375908
OpenAlexW3000756083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.